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Introduction
Hypoxia is a feature of solid tumours which generally
occurs over 100 µm away from functional blood vessels
[1], this O2 diffusion distance being determined by metab-
olism. As human tumours have an inadequate vasculature,
hypoxia is widespread in both primary tumours and their
metastases [2]. During tumour growth an increasingly
compromised blood supply generally results in a tumour
oxygen tension of 0–20 mmHg, compared with
24–66 mmHg in normal human tissues [3]. The majority of
these measurements in human tumours in vivo have been
performed using polarographic needle electrodes [2,3]
although other less invasive methods, which do not always
show good concordance, are at various stages of devel-
opment. These include magnetic resonance spectroscopy,
phosphorescence quenching microscopy and chemical
hypoxia probes such as pimonidazole. In addition to
chronic diffusion-limited hypoxia tumours can exhibit
regions of acute hypoxia, a transient state caused by per-
fusion fluctuations such as vessel closure, which is also
evident in both primary and metastatic human tumour
tissue [4]. Factors that have an impact on the rate of O2
utilisation, including the effects of oncogenic transforma-
tion on the metabolic rate of tumour tissue, also signifi-
cantly affect O2 levels [5].
In addition to being a consequence of the growth of a
malignant tumour and so a potential marker, hypoxia also
acts to promote tumour development. Hypoxic conditions
are known to affect the response of solid malignancies to
radiation, limiting its efficacy in both primary tumours and
metastatic tissue [6,7]. As well as conferring resistance to
current therapies, hypoxia can act as a negative clinical
prognostic indicator. An association between hypoxia and
metastatic potential has been demonstrated in human
tumours [6,8] with tumour oxygenation being a strong pre-
dictor of both overall and disease-free survival, regardless
of the mode of primary treatment [8]. The clinical impact of
hypoxia is supported by the results of trials suggesting
beneficial effects of blood transfusion or infusion of
recombinant human erythropoietin on treatment outcome,
particularly in response to radiotherapy [9].
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The basis for the association between hypoxia, tumourigen-
esis and malignant progression has been examined exten-
sively at both the molecular and the cellular level. Hypoxia
exerts direct effects on the expression of numerous gene
products involved in processes such as angiogenesis,
apoptosis, glycolysis and cell-cycle control, which are
central to the survival and expansion of a malignant cell
population in an oxygen-deficient environment. Hypoxia is
also known to mediate the recruitment of macrophages
and other immune cells into tumour tissue. These cells, in
turn, play a critical role in the balance between tumour
regression and progressive malignancy (Fig. 1).
Tumour angiogenesis
The main mechanism whereby a solid tumour mass can
overcome the proliferative limitations imposed by stressful
microenvironmental conditions and thus expand beyond
the microscopic level is to develop a nutritive blood supply.
This requires a switch from the constitutive anti-angiogenic
phenotype, involving a change in the balance of pro- and
anti-angiogenic molecules secreted from tumours and sur-
rounding cells, brought about by a combination of genetic
and microenvironmental stimuli, including hypoxia. Vascular
endothelial growth factor (VEGF) is a major pro-angiogenic
molecule that is mitogenic for endothelial cells and acts to
increase the vascular permeability of tumour blood vessels.
VEGF and one of its cellular receptors (flk-1) are signifi-
cantly upregulated in response to hypoxia [10,11], as are a
variety of other pro-angiogenic growth factors and their
receptors including platelet-derived growth factor-BB,
endothelin, nitric oxide synthase, insulin-dependent growth
factor-II, adrenomedullin and epidermal growth factor
receptor [11]. Oncogenic transformation of cells with acti-
vated ras has been shown to increase both the basal level
of VEGF mRNA expression and its degree of induction
under hypoxia. This is also true of other oncogenes includ-
ing egfr,  erbB2 and  raf, demonstrating that activation of
oncogene pathways can also switch on the angiogenic
phenotype [12].
As well as providing a physiological stimulus for the de
novo formation of tumour blood vessels, systemic hypoxia
is known to increase oxygen delivery to tumour tissues by
stimulating erythropoietin production. It was as a result of
the search for the molecular basis of this upregulation that
the hypoxia inducible factor (HIF) transcription factor was
discovered. HIF-1 (a heterodimeric transcription factor
composed of a hypoxia-inducible α subunit and a constitu-
tive β subunit) has been directly implicated in the hypoxic
upregulation of a number of the angiogenic growth
factors, including VEGF. The importance of the down-
stream effects of the HIF-mediated molecular response to
hypoxia on tumour growth has been dramatically demon-
strated in vivo. Abolition of the angiogenic growth factor
response to hypoxia in HIF-1α–/– embryonic stem cells
and Hepa1 cells lacking the aryl hydrocarbon receptor
Figure 1
Hypoxic regulation of pathways promoting tumour growth. The transcriptional level response to hypoxia is amplified by positive feedback
mechanisms and substantial crosstalk between the interconnecting pathways, thus providing a strong, co-ordinated response promoting
tumourigenesis and malignant progression. EC, endothelial cell; MCP-1, monocyte chemotactic protein 1; PBMC, peripheral blood mononuclear
cell; TAM, tumour-associated macrophage; VEGF, vascular endothelial growth factor.Breast Cancer Research    Vol 3 No 5 Knowles and Harris
nuclear translocator has generally resulted in xenografts
that demonstrate reduced vascularity compared to their
wild-type counterparts when grown as solid tumours in
vivo [13,14]. In a more recent study HIF-1α–/– tumours
exhibited no significant reduction in vascularity compared
with tumours derived from wild-type cells, despite a reduc-
tion in growth rate [15], although this discrepancy may be
cell-line specific. Generally, however, loss of the hypoxia-
stimulated angiogenic growth factor response has demon-
strated the importance of tumour vascularisation to the
growth and expansion of solid malignant tumours.
Apoptosis
As hypoxia is present prior to new blood vessel formation,
it is vital that tumour cells are able to adapt to a nutrient-
deficient environment and survive for long enough
periods for tumour progression to occur. It has recently
been shown that hypoxia is able to suppress the pro-
apoptotic effects of serum deprivation on both endothelial
cells and tumour cells via induction of VEGF [16,17]. In
HepG2 cells hypoxia inhibited apoptosis, reduced the
bax:bcl-2 ratio, decreased cytochrome c release and
decreased caspase 3 activity. These effects were
blocked by anti-VEGF neutralising antibodies or inhibitors
of receptor tyrosine kinase signalling [17]. This rescuing
effect of hypoxia could be mimicked by the addition of
recombinant human VEGF to serum-deprived cells. These
data suggest that the hypoxic induction of VEGF during
serum deprivation could be an adaptive response, making
tumour cells less susceptible to apoptosis-inducing
stimuli prior to initiation of new blood vessel formation
[17]. Although the role of VEGF receptors and their
degree of expression in tumour cell lines versus endothe-
lium is poorly studied, these results suggest that a more
detailed evaluation is warranted.
Another mechanism by which hypoxia subverts normal
mechanisms of apoptosis was described by Graeber et al
who demonstrated how hypoxia can act as a physiological
selective pressure promoting the clonal expansion of cells
with acquired mutations in components of the apoptotic
pathway [18]. Exposure of oncogenically-transformed
mouse embryonic fibroblast cells to multiple rounds of
hypoxia and aerobic recovery revealed the ability of
hypoxia to select for p53–/– (apoptosis resistant) over
p53WT cells. This in vitro data was supported by the
spatial relationship between hypoxia, p53 and apoptosis in
murine tumours in vivo, suggesting that hypoxia can
promote the clonal expansion of p53mut cells in areas of
tumour tissue where other cells will be killed by apoptosis
[18]. The relevance of these findings to human tumourige-
nesis is supported by data indicating that loss of p53WT is
associated with elevated levels of the apoptosis inhibitor
bcl-2, and the general observation that apoptosis is inhib-
ited during the development of human cancer [19,20].
This reduced p53:bcl-2 ratio (indicative of loss of both
cell-cycle control and regulation of the major apoptotic
pathway) acts to increase mutation rates within a clonal
cell population, aiding tumourigenesis and expansion of
solid malignancies. Passive selection of apoptosis-resis-
tant cells by a component of the tumour’s own microenvi-
ronment could help to explain why p53 is the most
commonly mutated gene in human cancer.
Importantly, it is not only anti-apoptotic pathways that are
selected under hypoxic conditions. Expression of the cell
death factor NIP3 is known to be upregulated by hypoxia
in a HIF-dependent manner in a variety of cancer cell lines
[21] and human tumours [22]. Large-scale gene expres-
sion studies have identified a number of pro-apoptotic or
growth-inhibitory genes that are specifically upregulated
under hypoxia, as well as those that promote tumour
growth [23]. It may be the case, therefore, that co-ordi-
nated regulation of a number a pro- and anti-apoptotic
pathways by both HIF-dependent and HIF-independent
mechanisms governs susceptibility to hypoxia-induced
apoptosis in a cell-type-specific manner.
The glycolytic shift
As insufficient oxygen is available for efficient ATP produc-
tion via the electron transport chain under hypoxic condi-
tions, another major cellular adaptation to hypoxia is the
switch of the respiratory pathway to anaerobic glycolysis.
This is associated with the high levels of glucose con-
sumption characteristic of solid tumour tissue [3] and is
necessary in order to maintain both the supply of precur-
sors of anabolic pathways (lipids, amino acids, nucleic
acids etc.) and cellular levels of ATP production within this
stressful environment.
Metabolic adaptation to tumour microenvironmental condi-
tions is a crucial step in tumour progression and hypoxia
acts to maximise the efficiency of the glycolytic shift on
several levels. Firstly, the expression of many key glycolytic
enzymes (including phosphoglycerate kinase 1, lactate
dehydrogenase A, pyruvate kinase M, glyceraldehyde-3-
phosphate dehydrogenase, enolase 1 and aldolase A) is
coordinately upregulated under hypoxia [24]. Secondly,
over-expression of the glucose transporter genes glut1
and glut3 is also known to be regulated by hypoxia and
has been demonstrated in human tumour tissues [13].
Thirdly, hypoxia can contribute more indirectly to the gly-
colytic phenotype; hypoxically-selected mutant p53 is able
to specifically transactivate glycolytic enzymes such as the
type II isoform of hexokinase [25]. The effects of hypoxia
can thus provide a direct link between the loss of cell-
cycle control and the high glycolytic rate of tumour cells.
Taken together, these gene expression changes enable
both maximal glucose uptake and a high efficiency of
glucose utilisation. Tumour cells, therefore, are able to
undergo glycolytic respiration, grow and proliferate under
more severe conditions than possible for normal cells.Available online http://breast-cancer-research.com/content/3/5/318
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The contribution of tumour-associated
macrophages
As well as modulating tumour biology at the molecular
level, hypoxia exerts cellular level effects on solid tumours.
Hypoxia is known to induce transendothelial migration of
monocytic cells from the peripheral circulation, which then
migrate into tumour tissue along gradients of chemokines
such as monocyte chemotactic protein 1 [26]. This migra-
tion is inhibited when a region of hypoxia is encountered
and the cells are then induced to accumulate and function
as tumour-associated macrophages (TAMs) [27]. This
process, therefore, acts to direct macrophages to areas of
necrosis or hypoxia where they exhibit a tumourigenic phe-
notype. Such macrophages have been associated with
angiogenesis and poor prognosis in invasive breast carci-
noma [28]. The molecular basis of the pro-angiogenic
activity of TAMs is similar to that of tumour cells them-
selves in that hypoxia induces the expression of a variety
of cytokines and growth factors. A key growth factor is
VEGF, which is thought to act on macrophages via a posi-
tive feedback mechanism. Hypoxia stimulates the produc-
tion of VEGF by both TAMs and tumour cells and it then
exerts a chemotactic action on macrophages, aiding their
migration to avascular tumour sites [29]. Macrophage-pro-
duced VEGF may then act in the angiogenic and anti-
apoptotic manner already discussed in order to further the
malignant phenotype.
Conclusions
It is clear that in addition to being a well-documented
marker of solid human tumour tissue, hypoxia also acts on
several levels to promote further tumour development. We
have highlighted mechanisms whereby hypoxia mediates
the switch to a pro-angiogenic phenotype, subverts normal
apoptotic pathways and maintains high levels of metabolic
activity within this stressful microenvironment. Using VEGF
as an example, we have also demonstrated the complex
interrelationships between these pathways. VEGF is a
major pro-angiogenic molecule that suppresses the pro-
apoptotic effects of serum deprivation under hypoxia and
contributes to the accumulation of TAMs in avascular
tumour sites, which then produce further VEGF as part of a
positive feedback mechanism. Antagonism of VEGF, there-
fore, may have multiple pathways of interaction with other
therapies, as well as direct antitumour effects.
It should be stressed that the genes discussed in this
review constitute only a fraction of those that have been
identified as being regulated by hypoxia. Gene expression
studies have defined numerous growth factors, glycolytic
enzymes, cytokines, transcription factors etc., which are
inducible by hypoxia, either by HIF-dependent or by HIF-
independent pathways. Many of these genes will act on
the major pathways that have been discussed while others
will have more distinct actions, for example the HIF-
inducible carbonic anhydrase 9 which might exert its bio-
logical effect through regulation of microenvironmental pH
[30]. As extracellular acidosis is also thought to promote
tumour growth, this adds yet another dimension to the
already complex nature of the contribution of hypoxia to
tumourigenesis.
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